27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The first single-stage individual patient data meta-analysis from randomized double-blind placebo-controlled clinical trials provides evidence to support benefits of antihypertensive treatment in late-mid and later life to lower the risk of dementia. 5 key findings →
Design: meta-analysis Participants: 28,008 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The global prevalence of MCI among community dwellers is over 15% and is affected by age, gender, education level and region of study sites. 4 key findings →
Design: systematic review Participants: 242,804 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The findings suggest that risk factors associated with ADRDs have changed over the past decade and differ based on sex and race and ethnicity. 5 key findings →
Design: meta-analysis Participants: 378 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
PA was associated with lower incidence of all-cause dementia and Alzheimer's disease, even in longer follow-ups, supporting PA as a modifiable protective lifestyle factor, even after reducing the effects of reverse causation. 5 key findings →
Design: meta-analysis Participants: 257,983 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Then, voxel-wise brainwide association analyses were used to identify gray matter volumes (GMVs) associated with social isolation and with loneliness. 5 key findings →
Design: cohort Participants: 462,619 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A large fraction of dementia cases in the US were associated with potentially modifiable risk factors, especially for Black and Hispanic individuals. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a significant public health challenge and may have greater incidence among older adults from underrepresented racial and ethnic minority groups. 4 key findings →
Design: cohort study Participants: 90 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
176 and 131 participants developed incident frailty, as measured with the FI and TFI respectively. 5 key findings →
Design: longitudinal study Participants: 131 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this prospective cohort study, higher consumption of UPF was associated with higher risk of dementia, whereas substituting unprocessed or minimally processed foods for UPF was associated with lower risk of dementia. 5 key findings →
Design: cohort Participants: 72,083 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this cohort study, a higher number of steps was associated with lower risk of all-cause dementia. 4 key findings →
Design: cohort Participants: 78,430 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Using datasets from a wide range of geographical regions, we found that both early life education and adulthood occupational complexity were independently predictive of dementia. 3 key findings →
Design: meta-analysis Participants: 10,195 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sleep apnea (SA) is potentially a modifiable risk factor for dementia. 5 key findings →
Design: meta-analysis Participants: 1,333,424 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The negative association between depression treatment and incident dementia was significant in the increasing and chronically low courses, highlighting the necessity of timely interventional strategies before depression progresses to a chronically severe state. 4 key findings →
Design: cohort Participants: 354,313 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Risk stratification is critical for the early identification of high-risk individuals and disease prevention. 3 key findings →
Participants: 117,981 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cox regression and accelerated failure time models were used to investigate whether sex, apolipoprotein E genotype and e4 carriage were associated with amyloid onset age in all cohorts. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Poststroke cognitive impairment and dementia (PSCID) is a major source of morbidity and mortality after stroke worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There was a significant interaction between PASE and MIND on executive functioning and total grey matter volume. 5 key findings →
Design: cross-sectional Participants: 132 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Delirium and dementia are two frequent causes of cognitive impairment among older adults and have a distinct, complex and interconnected relationship. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 774 incident dementia cases were diagnosed and validated, of which 518 were Alzheimer's disease (AD). 5 key findings →
Participants: 25,015 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Atrial cardiomyopathy, characterized by abnormalities in atrial structure and function, is associated with increased risk of adverse cardiovascular and neurocognitive outcomes, independent of atrial fibrillation. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke worldwide and confers one of the greatest risks of recurrent stroke compared with other causes of stroke. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD) differ by world region, suggesting that there are potentially modifiable risk factors for intervention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We review the epidemiologic data that led to the recommendation to use diastolic hypertension and proteinuria as diagnostic criteria, as their combined presence was associated with an increased risk of fetal death and the birth of small-for-gestational-age neonates. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The main form of vitamin D in all brain regions measured was 25(OH)D3 . 5 key findings →
Participants: 290 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →